Time for some fireworks and BBQ

July 4th is once again rolling around and FierceBiotech will be taking a brief retreat from deadlines to enjoy some fireworks and BBQ. But we'll be back bright and early on Thursday to resume our regular stream of R&D reports from the biopharma front. For our U.S. audience, we hope you have a safe and fun holiday. For the rest of the world, pardon the hiatus. Holidays happen. -- John Carroll, Editor-in-Chief. Follow me on Twitter and LinkedIn.

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.